BioNTech SE - American Depositary Shares (NQ:BNTX)

96.25 +0.25 (+0.26%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BioNTech SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

70 71 Next >

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

December 06, 2025

From BioNTech SE

Via GlobeNewswire

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

December 03, 2025

From BioNTech SE

Via GlobeNewswire

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Moderna, BioNTech Slammed After FDA Links Covid Shots To 10 Deaths ↗

December 01, 2025

Moderna tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children.

Via Investor's Business Daily

Topics Death

2 Top Dividend Stocks to Buy and Hold ↗

November 30, 2025

Patience will be rewarded for those who stick with these two healthcare stocks.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

BioNTech (BNTX) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

BioNTech (BNTX) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

November 26, 2025

From BioNTech SE

Via GlobeNewswire

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗

November 13, 2025

Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.

Via Benzinga

BioNTech Says Collaboration With Pfizer Going Strong After Report Indicated US Pharma Giant Considering Stake Sale In The German Company ↗

November 13, 2025

A BioNTech spokesperson told Reuters that the two companies continue to have a “close and strong collaboration.”

Via Stocktwits

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership ↗

November 03, 2025

BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization.

Via Benzinga

BioNTech SE (NASDAQ:BNTX) Reports Mixed Q3 2025 Results with Major Revenue Beat and Quarterly Loss ↗

November 03, 2025

BioNTech Q3 2025: Revenue surges on a $1.5B partnership payment, but company posts a net loss. Full-year sales guidance was raised significantly.

Via Chartmill

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

November 03, 2025

From BioNTech SE

Via GlobeNewswire

BioNTech to Host Innovation Series R&D Day on November 11, 2025

October 28, 2025

From BioNTech SE

Via GlobeNewswire

Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers

October 27, 2025

As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

October 27, 2025

From BioNTech SE

Via GlobeNewswire

2 Unstoppable Dividend Stocks Yielding More Than 4% That Income-Seeking Investors Will Want to Buy in November and Hold Forever ↗

October 25, 2025

Both companies are monsters in their industry and are poised to thrive.

Via The Motley Fool

Topics Government Intellectual Property World Trade

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

October 22, 2025

From BioNTech SE

Via GlobeNewswire

Beyond The Numbers: 7 Analysts Discuss BioNTech Stock ↗

October 10, 2025

Via Benzinga

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead ↗

October 08, 2025

These biotechs could finally come into their own by the end of the decade.

Via The Motley Fool

Topics Government World Trade

Healthcare Sector Shines Amidst Market Turbulence, Bolstering S&P 500 Resilience

October 02, 2025

On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Decoding Life's Blueprint: New Tech Maps RNA-Protein Interactions, Unlocking Disease Cures

October 02, 2025

A monumental leap in biomedical research has been announced with the development of a breakthrough technology capable of mapping the entire intricate network of RNA-protein interactions within human...

Via MarketMinute

Topics Artificial Intelligence Derivatives

Why BioNTech Stock Jumped by Nearly 4% on Wednesday ↗

October 01, 2025

The company's push deeper into a hot new technology, plus good news from a top collaborator, put the shine on its equity.

Via The Motley Fool

Topics Artificial Intelligence Government World Trade

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

September 23, 2025

From BioNTech SE

Via GlobeNewswire

Why BioNTech Stock Bumped Higher Today ↗

September 22, 2025

Investors were cheered by two pieces of good news concerning the biotech's most famous product.

Via The Motley Fool

CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids ↗

September 19, 2025

Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines.

Via Investor's Business Daily

The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut ↗

September 18, 2025

The reworked ACIP will make its debut Friday when the panelists weigh the suite of new Covid boosters.

Via Investor's Business Daily

Topics Government

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

September 18, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax ↗

September 16, 2025

Moderna's updated Spikevax shows strong antibody response and safety, targeting dominant COVID-19 variants like LP.8.1 in high-risk and older adults.

Via Benzinga

Oracle Retreats, Fed Rate Cut Looms, and Vaccine Politics Shake Pharma Stocks ↗

September 15, 2025

Markets closed Friday in mixed fashion as economic uncertainty and politics clashed with earnings optimism. Oracle's rollercoaster continues, RFK Jr. rattles vaccine makers, and the Fed appears poised...

Via Chartmill

Topics Artificial Intelligence Economy

< Previous 1 2 3 4 5 6 7 8 9

...

70 71 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.